Other nervous system drugs. Parasympathomimetics
ATC code: N07AX02 (Choline alfoscerate)
Brand names
Choline alfoscerate, Gliatilin
Proposed mechanism: on metabolism, releases choline, which is incorporated into neuronal membrane phospholipids and used for acetylcholine synthesis in cholinergic neurons. Manufacturers position the drug as a «neuroprotective» agent with cognitive effects. Clinical efficacy by these mechanisms is not confirmed in high-quality RCTs. International dementia, post-stroke cognitive impairment and Alzheimer disease guidelines do not mention the drug.
Not recommended
In Alzheimer disease, choline alfoscerate is not part of treatment standards. The has approved cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine; in recent years – anti-amyloid monoclonal antibodies (lecanemab, donanemab). Choline alfoscerate has no regulatory approval in the US or EU for Alzheimer disease. Prescribing delays initiation of effective disease-modifying therapy.
Sources
Not recommended
For complaints of impaired memory and concentration without an established diagnosis, choline alfoscerate is not used. 2018 recommends non-pharmacological interventions, vascular risk factor control, depression and drug side effect screening. «Neuroprotective» positioning does not meet evidence-based criteria. Before prescribing, the limitations of the evidence base and alternatives are openly discussed with the patient.
Not recommended
For post-stroke cognitive impairment, choline alfoscerate lacks an evidence base by international standards. EFNS 2012 and 2014 do not recommend it as a drug with confirmed efficacy. Post-stroke rehabilitation is based on cognitive training, physical rehabilitation, vascular risk factor control and depression treatment.
Not recommended
Evidence for choline alfoscerate in vascular dementia is lacking. High-quality long-term RCTs with clinically meaningful outcomes have not been published. The ASCOMALVA trial (2017), which reported positive results, has not been independently replicated and has been criticized for methodological limitations. International guidelines from , and EFNS do not mention the drug.
No FDA category assigned. The drug has no FDA approval. Safety data in pregnancy are insufficient. Not prescribed during pregnancy or breastfeeding.
Data on transfer into breast milk are insufficient. If treatment is necessary, breastfeeding is interrupted.
Choline alfoscerate is evaluated for the following indications with varying evidence strength: Alzheimer disease (evidence tier F), Vascular dementia (evidence tier F), Post-stroke cognitive impairment (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Choline alfoscerate (≥ 1 in 100): Nausea, Headache, Insomnia, less often drowsiness, Agitation, anxiety. See the Safety section for uncommon and serious reactions.
No FDA category assigned. The drug has no FDA approval. Safety data in pregnancy are insufficient. Not prescribed during pregnancy or breastfeeding.
Data on transfer into breast milk are insufficient. If treatment is necessary, breastfeeding is interrupted.
Choline alfoscerate is contraindicated in: Acute phase of hemorrhagic stroke (first 7 days); Pregnancy, breastfeeding (insufficient data); Age under 18 (insufficient data); Hypersensitivity to drug components. Full list in the Safety section.
modern medicine cannot restore dead neurons with any drug. «Neuroprotective» effects are experimental, with no confirmed clinical outcomes.
cognitive impairment prevention is based on vascular risk factor control, physical activity, Mediterranean diet, learning and social engagement. Course-based drug use without evidence is marketing.
country of origin is not evidence of efficacy. The drug is not FDA-approved and is not used in the US, UK, Germany or Canada.